Physician profile
Martha A Wright
NPI 1023240140
$1,261.53
in general payments reported to CMS, 2019-2025
15 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $118 · 2023: $126 · 2024: $435 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.61 |
| Education | $272.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $249.17 | 2021-2025 | Reblozyl, Revlimid |
| Abbvie INC. | $240.38 | 2024-2025 | |
| Janssen Biotech, INC. | $186.11 | 2023-2025 | Erleada, Imbruvica, Rybrevant |
| Aveo Pharmaceuticals, INC. | $126.20 | 2025 | |
| Incyte Corporation | $99.99 | 2022 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $82.70 | 2023-2025 | Talvey, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $38.06 | 2024 | |
| Genzyme Corporation | $26.36 | 2024 | |
| Beigene USA, INC. | $24.01 | 2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $21.94 | 2023 | |
| Geron Corporation | $20.74 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $16.37 | 2024 | Ultomiris |
| Emd Serono, INC. | $15.66 | 2024 | |
| Beone Medicines USA, INC. | $14.84 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.